Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Liver Cirrhosis

  Free Subscription


16.07.2018

1 BMC Gastroenterol
2 Gastroenterology
2 J Gastroenterol Hepatol
1 J Hepatol
4 PLoS One
1 Proc Natl Acad Sci U S A
1 Transplant Proc


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Gastroenterol

  1. LIU Z, Zhang Z, Huang M, Sun X, et al
    Taurocholic acid is an active promoting factor, not just a biomarker of progression of liver cirrhosis: evidence from a human metabolomic study and in vitro experiments.
    BMC Gastroenterol. 2018;18:112.
    PubMed     Text format     Abstract available


    Gastroenterology

  2. HARRISON SA, Abdelmalek MF, Caldwell S, Shiffman ML, et al
    Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
    Gastroenterology. 2018 Jul 7. pii: S0016-5085(18)34758.
    PubMed     Text format     Abstract available

  3. MOON AM, Weiss NS, Beste LA, Su F, et al
    No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-related Mortality in Patients with Cirrhosis.
    Gastroenterology. 2018 Jul 5. pii: S0016-5085(18)34721.
    PubMed     Text format     Abstract available


    J Gastroenterol Hepatol

  4. LIU CH, Liu CJ, Hong CM, Su TH, et al
    A noninvasive diagnosis of hepatic fibrosis by BioFibroScore(R) in chronic hepatitis C patients.
    J Gastroenterol Hepatol. 2017 May 26. doi: 10.1111/jgh.13834.
    PubMed     Text format     Abstract available

  5. CHEN YP, Hu XM, Liang XE, Huang LW, et al
    Stepwise application of fibrosis index based on four factors, red cell distribution width-platelet ratio, and aspartate aminotransferase-platelet ratio for compensated hepatitis B fibrosis detection.
    J Gastroenterol Hepatol. 2018;33:256-263.
    PubMed     Text format     Abstract available


    J Hepatol

  6. THULUVATH PJ, Kantsevoy S, Thuluvath AJ, Savva Y, et al
    Reply to: "NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis": Cryptogenic cirrhosis should not be equated with NASH cirrhosis based on UNOS data mining and Bayesian 'doctrine of chances'.
    J Hepatol. 2018 Jul 5. pii: S0168-8278(18)32168.
    PubMed     Text format    


    PLoS One

  7. KELLER S, Aigner A, Zenouzi R, Kim AC, et al
    Association of gadolinium-enhanced magnetic resonance imaging with hepatic fibrosis and inflammation in primary sclerosing cholangitis.
    PLoS One. 2018;13:e0193929.
    PubMed     Text format     Abstract available

  8. MIOTTO N, Mendes LC, Zanaga LP, Lazarini MSK, et al
    All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response.
    PLoS One. 2018;13:e0199941.
    PubMed     Text format     Abstract available

  9. SHAHEEN AA, Kaplan GG, Almishri W, Vallerand I, et al
    The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes.
    PLoS One. 2018;13:e0194839.
    PubMed     Text format     Abstract available

  10. BIAN S, Chen H, Wang L, Fei Y, et al
    Cardiac involvement in patients with primary biliary cholangitis: A 14-year longitudinal survey-based study.
    PLoS One. 2018;13:e0194397.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  11. HE X, Sun Y, Lei N, Fan X, et al
    MicroRNA-351 promotes schistosomiasis-induced hepatic fibrosis by targeting the vitamin D receptor.
    Proc Natl Acad Sci U S A. 2017 Dec 18. pii: 1715965115.
    PubMed     Text format     Abstract available


    Transplant Proc

  12. MIUMA S, Miyaaki H, Miyazoe Y, Suehiro T, et al
    Development of Duodenal Ulcers due to the Discontinuation of Proton Pump Inhibitors After the Induction of Sofosbuvir Plus Ledipasvir Therapy: A Report of Two Cases.
    Transplant Proc. 2018;50:222-225.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: